Rep. Doug Lamborn

Maddy summaryThis bill creates a new federal crime for assaulting law enforcement officers causing serious injury or death, with penalties up to 10 years in prison for serious injury and up to life for aggravated cases involving death, kidnapping, or attempted killing. It applies when offenses involve interstate travel, commerce, or target officers engaged in law enforcement duties. Federal prosecution requires Attorney General certification that state authorities cannot or will not handle the case, or that federal action is necessary for public safety. The law covers all law enforcement officers (state, local, and federal) who enforce criminal laws or detain individuals.

Repealing Illegal Freedom and Liberty Excises Act or the RIFLE Act This bill repeals the excise tax on the transfer of firearms. The bill shall not be construed as placing any regulated firearms under the jurisdiction of the U.S. Consumer Product Safety Commission.

Prohibition of Agricultural Land for the People's Republic of China Act This bill requires the President to prohibit nonresident aliens, foreign businesses, and agents associated with China's government from (1) purchasing agricultural (including ranching) real estate located in the United States, or (2) participating in Department of Agriculture programs that are unrelated to food and safety regulatory requirements.

Maddy summaryHR 720, the Davis-Bacon Repeal Act, would eliminate the Davis-Bacon wage requirements for federal construction projects. It directly affects federal contractors working on projects funded by the government, removing a longstanding rule that required them to pay prevailing wages. The bill repeals Subchapter IV of Chapter 31 in Title 40 of the U.S. Code, which established these wage standards. The repeal would take effect 30 days after enactment but would not impact existing contracts or bids outstanding on that date.

Protecting Life and Integrity in Research Act of 2023 This bill restricts research that uses human fetal tissue from an induced abortion. Specifically, it prohibits the Department of Health and Human Services from conducting or supporting such research. Additionally, the bill applies requirements on the research of transplantation of fetal tissue for therapeutic purposes to research on fetal tissue in general. The bill also prohibits soliciting or acquiring a donation of human fetal tissue from an induced abortion, other than for purposes of an autopsy or burial.

Maddy summaryThis bill would prohibit the FDA from approving new abortion medications or investigational uses of existing ones. It would restrict currently approved abortion drugs to in-person administration only in clinics, hospitals, or medical offices by certified providers who can handle complications like ectopic pregnancy or severe bleeding. The law requires detailed adverse event reporting (excluding patient identifiers) to the FDA by both manufacturers and prescribers, and mandates provider certification covering pregnancy assessment, surgical intervention capabilities, and patient safety documentation. These provisions apply directly to healthcare providers, patients seeking medication abortions, and manufacturers of abortion drugs.

This bill nullifies certain changes made by the Food and Drug Administration (FDA) to dispensing requirements for mifepristone. (Mifepristone is a drug that is approved to end pregnancies through 10 weeks gestation when used in conjunction with the drug misoprostol. The procedure is often referred to as medication abortion or the abortion pill.) The FDA regulates the use of mifepristone through the Mifepristone Risk Evaluation and Mitigation Strategy (REMS) program. The program requires health care providers to comply with certain requirements in order to prescribe or dispense mifepristone to end a pregnancy; the program previously included an in-person dispensing requirement that required mifepristone to be directly dispensed to patients in clinics, medical offices, or hospitals. During the COVID-19 public health emergency, the FDA temporarily stopped enforcing the in-person dispensing requirement, which allowed mail-order pharmacies to fill and dispense mifepristone prescriptions. In January 2023, the FDA modified program requirements so as to (1) remove the in-person dispensing requirement, and (2) require pharmacies to be certified in the program in order to dispense mifepristone. The modifications allow retail pharmacies, after receiving certification, to dispense mifepristone pursuant to prescriptions that are written by program-certified prescribers. The bill nullifies the January 2023 changes and prohibits any similar changes in the future.

Protecting Life from Chemical Abortions Act This bill nullifies certain changes made by the Food and Drug Administration (FDA) to dispensing requirements for mifepristone. (Mifepristone is a drug that is approved to end pregnancies through 10 weeks gestation when used in conjunction with the drug misoprostol. The procedure is often referred to as medication abortion or the abortion pill.) The FDA regulates the use of mifepristone through the Mifepristone Risk Evaluation and Mitigation Strategy (REMS) program. The program requires health care providers to comply with certain requirements in order to prescribe or dispense mifepristone to end a pregnancy; the program previously included an in-person dispensing requirement that required mifepristone to be directly dispensed to patients in clinics, medical offices, or hospitals. During the COVID-19 public health emergency, the FDA temporarily stopped enforcing the in-person dispensing requirement, which allowed mail-order pharmacies to fill and dispense mifepristone prescriptions. In January 2023, the FDA modified program requirements so as to (1) remove the in-person dispensing requirement, and (2) require pharmacies to be certified in the program in order to dispense mifepristone. The modifications allow retail pharmacies, after receiving certification, to dispense mifepristone pursuant to prescriptions that are written by program-certified prescribers. The bill nullifies the January 2023 changes and prohibits the FDA from (1) exercising any enforcement discretion with respect to program requirements, or (2) reducing program protections until every state submits certain data regarding abortions to the Centers for Disease Control and Prevention. The bill also generally prohibits the declaration of a public health emergency with respect to abortions.

Maddy summaryHCONRES 7 is a symbolic resolution passed by the U.S. House of Representatives that commends Iranian protesters - particularly women - who have risked safety to demonstrate against the Iranian regime's human rights abuses, including the mandatory hijab law and violent crackdowns following Mahsa Amini's death. It condemns the regime's use of violence (reportedly killing over 450 protesters) and detention of activists, while urging the Biden Administration to impose additional human rights sanctions on officials involved in repression and support internet freedom tools to bypass Iranian censorship. The resolution makes no binding policy changes but formally expresses congressional support for protesters' demands for freedom, justice, and an end to discriminatory laws targeting women. It does not directly affect any U.S. laws or policies but serves as a statement of U.S. position.

Maddy summaryThe Educational Choice for Children Act creates tax credits for individuals and corporations that contribute to scholarship granting organizations providing education scholarships. Individuals can claim a credit up to $5,000 or 10% of their income, while corporations can claim up to 5% of taxable income. The scholarships are available to students from households with income up to 300% of the area median income, and can be used for private school tuition, tutoring, and other educational expenses at elementary and secondary schools. The bill includes strict requirements for scholarship organizations to verify income, conduct audits, and prevent misuse of funds, while also prohibiting government control over these organizations and protecting private and religious schools from discrimination in the program. It establishes a $10 billion annual cap on the total tax credits available.